Eosinophilic Esophagitis clinical trials at UCSF
2 research studies open to eligible people
Eosinophilic esophagitis is a disease that makes swallowing difficult due to a buildup of white blood cells in the esophagus. UCSF is researching Dupilumab's potential to improve swallowing function over time in adults. A separate study looks at Dupilumab in adolescents with eosinophilic gastritis and checks for side effects.
Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial)
open to eligible people ages 18 years and up
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate…
San Francisco, California and other locations
Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
open to eligible people ages 12 years and up
This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. …
San Francisco, California and other locations
Last updated: